乳腺癌中成纤维细胞生长因子受体1的临床应用进展

Research progression and clinical application of FGFR-1 in breast cancer

乳腺癌是影响全世界女性健康的主要恶性肿瘤,以放化疗、内分泌治疗、靶向治疗及免疫治疗等综合治疗为主。但乳腺癌短期内复发、转移是限制临床疗效和导致患者预后差的重要因素,而影像学检查和传统血清标记物却难以及时有效地监测肿瘤的复发转移,导致临床治疗决策迟滞。因此,研发灵敏、准确、非侵入性的疗效监测方法至关重要。多项研究证实检测FGFR1的扩增对于肿瘤的早期诊断、用药指导、复发监测有着巨大的应用潜力。本文对FGFR1在乳腺癌中的临床应用研究进展给予阐述。

Breast cancer is a major malignant tumor affecting the health of women all over the world.Its treatment methods include radiotherapy,chemotherapy,endocrine therapy,targeted therapy,and immunotherapy.However,the short-term recurrence and metastasis of breast cancer are important factors limiting the clinical efficacy and leading poor prognosis.Imaging examinations and traditional serum markers are difficult to monitor tumor recurrence and metastasis timely and effectively,which lead to delays in the clinical treatment decisions.Therefore,it is very important to develop sensitive,accurate and non-invasive methods to monitor the efficacy.A number of studies have confirmed that the detection of FGFR1 amplification has a great potential for early diagnosis,drug guidance,and recurrence monitoring of tumor.This article reviews the progression of clinical application of FGFR1 in breast cancer.